URGN earnings analysis
What we found in URGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
UroGen Pharma reported a notably strong Q1 2026 with revenue increasing to $51.0 million, surpassing estimates and representing a 152% year-over-year growth. This surge was primarily driven by the successful launch of Zusduri, which contributed $29.2 million in sales. The company also marked a significant narrowing of net losses, reflecting operational improvements and successful product deployment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Robust Revenue Growth
- Revenue reached $51.0 million for Q1 2026, up from $20.3 million in Q1 2025, marking a 152% year-over-year increase.
- Successful Launch of Zusduri
- Sales from Zusduri amounted to $29.2 million, significantly boosting overall revenue.
- Decreased Net Loss
- Net loss decreased to $23.6 million from $43.8 million year-over-year, an improvement of $20.3 million.
- Narrowing Operating Loss
- Operating loss improved to $20.3 million from $36.9 million year-over-year, a $16.7 million reduction.
- Continued Cash Generation
- As of March 31, 2026, UroGen maintained $140.3 million in cash and equivalents, providing a solid buffer for operations.
- Increased Inventory Buffer
- The company has built a buffer inventory of over 12 months of bulk mitomycin, enhancing supply chain stability.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operational Expenses
- Operating expenses increased to $67.1 million in Q1 2026, up from $54.8 million, driven by selling and marketing for Zusduri.
- Regulatory Risk
- Compliance with FDA regulations remains a significant ongoing requirement that could introduce unexpected operational challenges.
- Dependence on Critical Drugs
- The company's financial success is heavily reliant on the market acceptance of its new drug Zusduri, which may not meet expected adoption.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.47
- Segment
- Zusduri: $29.2M
- Segment
- Jelmyto: $21.8M
What they said about what is next.
UroGen anticipates revenue from JELMYTO to range between $97 million and $101 million for 2026, while guidance for ZUSDURI is not yet provided.
The filing reads better than the one before it.
What came before.
- 10-K · March 2, 2026
- UroGen reported meaningful top-line growth in 2025, driven by commercial traction for its RTGel-based products, with full-year revenue of $109.0M (sum of quarterly results) versus $91.0M in 2024 (≈+19.8%). Gross margins…
- 10-Q · November 6, 2025
- UroGen reported Q3 revenue of $27,482 (in thousands) and GAAP net loss of $33,347 (in thousands), or $(0.69) per share. Gross profit increased to $24,204 but the company’s operating loss widened to $(27,386) driven by…
- 10-Q · August 7, 2025
- UroGen reported quarter revenue of $24,215 (in thousands), up from $21,848 in Q2 2024, driven by product sales including the recent commercial launch activity. Profitability deteriorated: gross margin remained healthy…
- 10-Q · May 12, 2025
- UroGen reported Q1 revenue of $20,254,000 (up from $18,781,000 a year ago) with a high gross margin of 88.6% (gross profit $17,924,000). Despite revenue growth, operating loss widened to $36,914,000 and net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing URGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever